News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Merck KGaA Cancer Drug Erbitux Seen Limited Threat To Roche Holding AG and Genentech, Inc. Avastin
June 2, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, June 2 (Reuters) - Roche Holding AG shares jumped while Merck KGaA fell on Monday as investors decided rival drug Erbitux posed no immediate threat to Roche and Genentech Inc's cancer blockbuster Avastin.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Genentech, Inc.
MORE ON THIS TOPIC
Deals
Ipsen sends clear Memo to rare diseases with up to $796M buyout
July 1, 2026
·
2 min read
·
Gabrielle Masson
Approvals
Orca opens up Treg cell therapy with FDA nod for allogeneic blood cancer treatment
July 1, 2026
·
2 min read
·
Heather McKenzie
Neuropsychiatric disorders
Vistagen in freefall as social anxiety drug fails Phase 3
July 1, 2026
·
2 min read
·
Tristan Manalac
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
·
2 min read
·
Jef Akst
